T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.
Marieke J. Krimphove,Alexander P. Cole,Sean A. Fletcher,Sabrina S. Harmouch,Sebastian Berg,Sebastian Berg,Stuart R. Lipsitz,Maxine Sun,Maxine Sun,Junaid Nabi,Paul L. Nguyen,Jim C. Hu,Adam S. Kibel,Toni K. Choueiri,Luis A. Kluth,Quoc-Dien Trinh +15 more
TL;DR: The authors' analysis of men with advanced PCa revealed worse OS among Blacks, but when access to care, treatment, and cancer characteristics are accounted for, Black race was associated with better OS, suggesting that initiatives to improveAccess to care may represent an effective tool to reduce disparities in PCa outcomes.
Journal ArticleDOI
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma
Rony M. Abou-Jawde,Rachid Baz,Esteban Walker,Toni K. Choueiri,Mary Ann Karam,Janice Reed,Beth Faiman,Mohamad A. Hussein +7 more
TL;DR: This paper found that the median age was 60 years and 38 patients were African-Americans, and the mean distance traveled was 67.7 miles, while race, distance traveled and socioeconomic status were not independent prognostic factors for overall survival.
Journal ArticleDOI
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Amin Nassar,Amin Nassar,Kent W. Mouw,Opeyemi Jegede,Atul B. Shinagare,Jaegil Kim,Chia Jen Liu,Mark Pomerantz,Lauren C. Harshman,Eliezer M. Van Allen,Xiao X. Wei,Bradley Alexander McGregor,Atish D. Choudhury,Mark A. Preston,Fei Dong,Sabina Signoretti,Sabina Signoretti,Neal I. Lindeman,Joaquim Bellmunt,Toni K. Choueiri,Guru Sonpavde,David J. Kwiatkowski,David J. Kwiatkowski +22 more
TL;DR: This three-factor model includes genomic (SNV count >9) and clinical (NLR <5, lack of visceral metastasis) variables predictive for benefit to ICI but not taxane therapy for mUC.
Journal ArticleDOI
Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics
David F. Friedlander,Quoc-Dien Trinh,Anna Krasnova,Stuart R. Lipsitz,Maxine Sun,Paul L. Nguyen,Adam S. Kibel,Toni K. Choueiri,Joel S. Weissman,Mani Menon,Firas Abdollah +10 more
TL;DR: Significant differences in rates of radiation and surgical treatment for prostate cancer among White and Black men are found, with most facilities favoring Whites.
Journal ArticleDOI
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
Toni K. Choueiri,Robert Dreicer,Brian I. Rini,Paul Elson,Jorge A. Garcia,Snehal G. Thakkar,Rachid Baz,Tarek Mekhail,Holly A. Jinks,Ronald M. Bukowski +9 more
TL;DR: Lenalidomide (LEN) is a structural and functional analogue of thalidomides that has demonstrated enhanced immunomodulatory properties and a more favorable toxicity profile.